Year-end Sale % OFF 
Abstract
Ribosomes: the future of targeted therapies?
Highlights
Ribosomes are ribo-nucleoprotein complexes that read mRNA to synthesize protein during translation
Dyskeratosis congenita which is characterized by premature aging and increase in cancer susceptibility, is associated with expression of mutant DKC1 enzyme that is involved in pseudo-uridylation of ribosomal RNA (rRNA) [3]
The catalytic activity of ribosomes is driven by rRNA, whose dynamic changes of structure are involved in both mRNA decoding and formation of peptide bonds. rRNA chemical modifications, which include pseudouridylation and ribose methylation, are essential for maintaining rRNA structures as well as RNA:RNA and RNA:protein interactions, and it has been shown that their alteration directly affects intrinsic ribosome activity during translation
Summary
Ribosomes are ribo-nucleoprotein complexes that read mRNA to synthesize protein during translation. Dyskeratosis congenita which is characterized by premature aging and increase in cancer susceptibility, is associated with expression of mutant DKC1 enzyme that is involved in pseudo-uridylation of rRNA [3]. Mutant DKC1 modifies the rRNA pseudo-uridylation pattern of ribosomes and reduces translational efficiency of a distinct subset of mRNAs that are at the origin of the pathology and of cancer susceptibility.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
